BIO-TECHNE Corp
Form 3
December 03, 2014

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0104
Expires:	January 31, 2005
Estimated average burden hours per response...	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Â Gavin Robert M.
(Last) (First) (Middle)

C/O BIO-TECHNE CORPORATION,Â 614 MCKINLEY PLACE NE
(Street)

MINNEAPOLIS,Â MNÂ 55413
(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/25/2014

3. Issuer Name **and** Ticker or Trading Symbol
BIO-TECHNE Corp [TECH]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director
_____ 10% Owner
__X__ Officer (give title below)
_____ Other (specify below)
Sen. VP Protein Platforms

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,000 (1)	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option	07/31/2015(2)	07/31/2021	Common Stock	10,000	$ 93.32	D	Â
Stock Option	01/01/2017(3)	07/31/2021	Common Stock	50,000	$ 93.32	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Gavin Robert M. C/O BIO-TECHNE CORPORATION 614 MCKINLEY PLACE NE MINNEAPOLIS,Â MNÂ 55413	Â	Â	Â Sen. VP Protein Platforms	Â

Signatures

/s/ Robert M. Gavin	12/03/2014
**Signature of Reporting Person	Date

Explanation of Responses:

***** If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

****** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes 5,000 restricted stock units that represent a contingent right to receive one share of Bio-Techne Corporation common stock. The restricted stock units vest if certain performance goals are achieved for calendar 2016.

(2) Vests 2,500 on each of 7/31/2015, 7/31/2016, 7/31/2017 and 7/31/2018.

(3) Includes 50,000 common stock options. The options vest if certain performance goals are achieved for calendar 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.